Rapid responses are electronic letters to the editor. They enable our users to debate issues raised in articles published on thebmj.com. Although a selection of rapid responses will be included online and in print as readers' letters, their first appearance online means that they are published articles. If you need the url (web address) of an individual response, perhaps for citation purposes, simply click on the response headline and copy the url from the browser window. Letters are indexed in PubMed.
Cancer Research UK has a responsibility for bringing new types of treatment to patients which it takes very seriously. We want to ensure that all our trials are properly reported so we can act on positive findings and avoid repeating negative ones.
In the last decade, Cancer Research UK has managed the treatment of patients in 25 different trials of very new types of treatment (phase I and II trials). Of these 20 have already been published and the remaining five are in the process of being analysed.
Cancer Research UK has also helped finance a further 298 trials of more established treatments (late phase trials) organised by hospital trusts or universities and now completed. Of these, 183 have reported results to date and the remaining 115 trials have yet to be fully analysed. One of the reasons for this is that a trial cannot generally report until a pre-defined time point has been reached or a specified number of events have occurred.
We recognise our duty to carry out research to the highest possible standards, and believe that information from trials should be published as soon as the results are shown to be reliable. We will be responding to the Science and Technology Select Committee inquiry into clinical trials and disclosure of data, where we will outline our position in more detail.
Professor Peter Johnson
Cancer Research UK
No competing interests
31 January 2013
Peter W M Johnson
Cancer Research UK
Angel Building, 407 St John's Street, London EC1V 4AD